A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis

BMC Genomics

Volumn 19, Issue 1, 2018, Pages

  Liu, Jie ^a,b   Xiao, Yue ^a   Wu, Xikun ^a   Jiang, Lichun ^a   Yang, Shurong ^a   Ding, Zhiming ^a   Fang, Zhuo ^a   Hua, Haiqing ^a   Kirby, Mark Stephen ^a   Shou, Jianyong ^a,b  

^a Lilly China Research and Development Center   (China)

^b Fosun Kite Biotechnology ^*  (China)

Author keywords

ALT; Biomarker; MicroRNA; MiR 192; MiR 21; MiR 505; NASH

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; CIRCULATING MICRORNA; MICRORNA; MICRORNA 122; MICRORNA 192; MICRORNA 21; MICRORNA 29A; MICRORNA 34A; MICRORNA 505; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; MALE; MEASUREMENT ACCURACY; MOUSE; MOUSE MODEL; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROGNOSIS; UPREGULATION; VALIDATION PROCESS; ANIMAL; BLOOD; C57BL MOUSE; DISEASE EXACERBATION; GENETICS; HUMAN; LIVER; METABOLISM;

ANIMALS; BIOMARKERS; CIRCULATING MICRORNA; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; LIVER; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS;

EID: 85043477718     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-018-4575-3     Document Type: Article

References (43)

1. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913-24.
2. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330-44.
3. Sanyal AJ, Friedman SL, McCullough AJ, Dimick-Santos L, American Association for the Study of Liver D, United States F, Drug A. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration joint workshop. Hepatology. 2015;61(4):1392-405.
4. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, Grimaldi A, Capron F, Poynard T, Group LS. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128(7):1898-906.
5. Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8(2):93-103.
6. Momen-Heravi F, Saha B, Kodys K, Catalano D, Satishchandran A, Szabo G. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med. 2015;13:261.
7. Baldassarre A, Felli C, Prantera G, Masotti A. Circulating microRNAs and bioinformatics tools to discover novel diagnostic biomarkers of pediatric diseases. Genes (Basel). 2017;8(9):234.
8. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861-74.
9. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol. 2012;13(4):239-50.
10. Deiuliis JA. MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes. 2016;40(1):88-101.
11. Roderburg C, Luedde T. Circulating microRNAs as markers of liver inflammation, fibrosis and cancer. J Hepatol. 2014;61(6):1434-7.
12. Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800-12.
13. Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Mullhaupt B, Geier A. Performance of serum microRNAs-122,-192 and-21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One. 2015;10(11):e0142661.
14. Chen YJ, Zhu JM, Wu H, Fan J, Zhou J, Hu J, Yu Q, Liu TT, Yang L, Wu CL, et al. Circulating microRNAs as a fingerprint for liver cirrhosis. PLoS One. 2013;8(6):e66577.
15. Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakir O, Dundar M, et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol. 2014;6(8):613-20.
16. Pogribny IP. MicroRNAs as biomarkers for clinical studies. Exp Biol Med (Maywood). 2018;243(3):283-90.
17. Sarkar N. Circulating microRNAs as markers for liver histological lesions in patients with nonalcoholic steatohepatitis. AASLD LiverLearning. 2016;143957. Abstract ID:1063.
18. Francque S. LBP-535 - next-generation sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis. J Hepatol. 2017;66(1):S110-1.
19. DiStefano JK, Gerhard GS. Circulating microRNAs in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2016;10(2):161-3.
20. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99-103.
21. Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J, Athanacio J, Villescaz C, Ghosh SS, Heilig JS, et al. Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol. 2013;305(7):G483-95.
22. Xia J, Wishart DS. Using MetaboAnalyst 3.0 for comprehensive metabolomics data analysis. Curr Protoc Bioinformatics. 2016;55:14 10 11-14 10 91.
23. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8.
24. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
25. Xia MF, Lin HD, Yan HM, Bian H, Chang XX, Zhang LS, He WY, Gao X. The association of liver fat content and serum alanine aminotransferase with bone mineral density in middle-aged and elderly Chinese men and postmenopausal women. J Transl Med. 2016;14:11.
26. Fallatah HI, Akbar HO, Fallatah AM. Fibroscan compared to FIB-4, APRI, and AST/ALT ratio for assessment of liver fibrosis in Saudi patients with nonalcoholic fatty liver disease. Hepat Mon. 2016;16(7):e38346.
27. Rath MM, Panigrahi MK, Pattnaik K, Bhuyan P, Kar SK, Misra B, Misra D, Meher C, Agrawal O, Rath J, et al. Histological evaluation of non-alcoholic fatty liver disease and its correlation with different noninvasive scoring systems with special reference to fibrosis: a single center experience. J Clin Exp Hepatol. 2016;6(4):291-6.
28. Roy S, Benz F, Alder J, Bantel H, Janssen J, Vucur M, Gautheron J, Schneider A, Schuller F, Loosen S, et al. Down-regulation of miR-192-5p protects from oxidative stress-induced acute liver injury. Clin Sci. 2016;130(14):1197-207.
29. Roderburg C, Benz F, Vargas Cardenas D, Koch A, Janssen J, Vucur M, Gautheron J, Schneider AT, Koppe C, Kreggenwinkel K, et al. Elevated miR-122 serum levels are an independent marker of liver injury in inflammatory diseases. Liver Int. 2015;35(4):1172-84.
30. Wu K, Ye C, Lin L, Chu Y, Ji M, Dai W, Zeng X, Lin Y. Inhibiting miR-21 attenuates experimental hepatic fibrosis by suppressing both the ERK1 pathway in HSC and hepatocyte EMT. Clin Sci. 2016;130(16):1469-80.
31. Wei J, Feng L, Li Z, Xu G, Fan X. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother. 2013;67(5):387-92.
32. Knabel MK, Ramachandran K, Karhadkar S, Hwang HW, Creamer TJ, Chivukula RR, Sheikh F, Clark KR, Torbenson M, Montgomery RA, et al. Systemic delivery of scAAV8-encoded MiR-29a ameliorates hepatic fibrosis in carbon tetrachloride-treated mice. PLoS One. 2015;10(4):e0124411.
33. Matsumoto Y, Itami S, Kuroda M, Yoshizato K, Kawada N, Murakami Y. MiR-29a assists in preventing the activation of human stellate cells and promotes recovery from liver fibrosis in mice. Mol Ther. 2016;24(10):1848-59.
34. Di Mauro S, Ragusa M, Urbano F, Filippello A, Di Pino A, Scamporrino A, Pulvirenti A, Ferro A, Rabuazzo AM, Purrello M, et al. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: clinical implications. Nutr Metab Cardiovasc Dis. 2016;26(12):1129-39.
35. Povero D, Eguchi A, Li H, Johnson CD, Papouchado BG, Wree A, Messer K, Feldstein AE. Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease. PLoS One. 2014;9(12):e113651.
36. Liu XL, Cao HX, Wang BC, Xin FZ, Zhang RN, Zhou D, Yang RX, Zhao ZH, Pan Q, Fan JG. miR-192-5p regulates lipid synthesis in non-alcoholic fatty liver disease through SCD-1. World J Gastroenterol. 2017;23(46):8140-51.
37. Takeuchi-Yorimoto A, Yamaura Y, Kanki M, Ide T, Nakata A, Noto T, Matsumoto M. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease. Toxicol Lett. 2016;258:159-67.
38. Rodrigues PM, Afonso MB, Simao AL, Carvalho CC, Trindade A, Duarte A, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM, et al. miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice. Cell Death Dis. 2017;8(4):e2748.
39. Chen S, Sun KX, Liu BL, Zong ZH, Zhao Y. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-alpha. Mol Cancer. 2016;15:11.
40. Loyer X, Paradis V, Henique C, Vion AC, Colnot N, Guerin CL, Devue C, On S, Scetbun J, Romain M, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression. Gut. 2016;65(11):1882-94.
41. Lu L, Qiu C, Li D, Bai G, Liang J, Yang Q. MicroRNA-505 suppresses proliferation and invasion in hepatoma cells by directly targeting high-mobility group box 1. Life Sci. 2016;157:12-8.
42. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(Database issue):D163-9.
43. Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, McGinn CM, DePeralta DK, Chen X, Kuroda T, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology. 2014;59(4):1577-90.